Quick Answer
Thyroid nodule workup and thyroid cancer surgery deliver 2-3 NEET PG questions per year, especially in AIIMS-style clinical scenarios.
- TSH first — low → uptake scan (hot nodule rarely malignant); normal/high → USG + FNAC.
- TI-RADS 4-5 or Bethesda IV-VI → surgery.
- Cancer histology — PTC (70 percent, lymphatic, Orphan Annie nuclei) > FTC (10 percent, haematogenous, invasion needed) > MTC (5 percent, calcitonin, RET, MEN 2) > ATC (2 percent, elderly, lethal).
- Surgery — hemi (unilateral, small DTC) vs total (bilateral, high-risk, MTC, retrosternal, ATC).
- Complications — RLN palsy (1-2 percent), superior laryngeal external branch, hypocalcaemia, haematoma, hypothyroidism.
- Adjuvant — radioactive iodine ablation for intermediate/high-risk DTC after total thyroidectomy.
- India — persistent iodine deficiency belt in Sub-Himalayan regions; rising incidental micro-PTC in young women.
Thyroid surgery is one of the busiest general-surgery MCQ topics — solitary nodule workup, cancer histology, choice of operation, and the classic complications tested year after year. Rising incidental papillary micro-carcinoma in young Indian women, the 2023 Bethesda refresh, and MEN 2 prophylactic thyroidectomy make this a topic where updates matter.
This NEETPGAI deep dive walks through the modern nodule workup (TSH → USG TI-RADS → Bethesda FNAC → molecular testing), goitre subtypes, the four histological cancers, hemi vs total thyroidectomy, RAI, RLN and parathyroid complications, and Indian tertiary practice. Pair this with the thyroid disorders complete guide for endocrinology framing and the young woman with thyroid storm clinical case for the medical emergency corollary.
Thyroid nodule workup — the modern algorithm
Step 1 — Serum TSH
- Low TSH → order Tc-99m pertechnetate or I-123 uptake scan. A hot nodule (autonomous) is almost never malignant → treat the hyperthyroidism (RAI, surgery, antithyroid drug) and defer FNAC.
- Normal or high TSH → proceed to ultrasound.
Step 2 — Ultrasound (TI-RADS or ATA sonographic categories)
Ultrasound features that raise malignancy suspicion:
- Hypoechogenicity
- Taller-than-wide shape (anteroposterior more than transverse in axial plane)
- Microcalcifications (correlate with psammoma bodies of PTC)
- Irregular or spiculated margins
- Extrathyroidal extension
- Suspicious lymph nodes (round, hyperechoic, microcalcifications, cystic change, abnormal vascularity)
ACR TI-RADS scoring stratifies nodules TR1 (benign) through TR5 (highly suspicious) with size thresholds for FNAC. TR5 nodules ≥ 10 mm need FNAC; TR4 nodules ≥ 15 mm; TR3 nodules ≥ 25 mm; TR1-2 need no FNAC.
Step 3 — Fine-needle aspiration cytology (Bethesda 2023)
| Bethesda | Category | Malignancy risk | Management |
|---|
| I | Nondiagnostic / unsatisfactory | 5-10 percent | Repeat US-guided FNAC |
| II | Benign | 0-3 percent | Clinical + USG follow-up |
| III | AUS / FLUS (atypia of undetermined significance) | 10-30 percent | Repeat FNAC or molecular testing |
| IV | Follicular neoplasm / suspicious for follicular neoplasm | 25-40 percent | Hemithyroidectomy or molecular testing |
| V | Suspicious for malignancy | 60-75 percent | Hemithyroidectomy at minimum |
| VI | Malignant | 97-99 percent | Total thyroidectomy for high-risk features |
Step 4 — Molecular testing (for indeterminate III and IV)
- Afirma GSC (Gene Sequencing Classifier) — high negative predictive value; downgrades many indeterminate nodules to benign.
- ThyroSeq v3 — sequences 112 genes; higher positive predictive value.
- India — availability limited to tertiary centres; cost is the main barrier.
Goitre — types and management
| Type | Feature | Management |
|---|
| Simple / endemic | Iodine deficiency; euthyroid diffuse enlargement | Iodised salt (National Iodine Deficiency Disorders Control Programme, NIDDCP) |
| Multinodular goitre (MNG) | Multiple nodules; euthyroid or hyperthyroid (toxic MNG); can host malignancy in about 5 percent | Follow if asymptomatic euthyroid; surgery for cosmesis, pressure symptoms, toxic, or suspicious nodule |
| Toxic diffuse (Graves disease) | Autoimmune (TSI/TRAb); ophthalmopathy, pretibial myxoedema | Antithyroid drugs (carbimazole/methimazole), RAI, or thyroidectomy |
| Toxic adenoma / toxic MNG | Autonomous hot nodule(s) | RAI or surgery preferred over long antithyroid drug |
| Retrosternal goitre | Extends below thoracic inlet | Surgery for airway compromise; Pemberton sign (facial plethora on arms-up test) |
Iodine deficiency remains regionally prevalent in India — the Himalayan foothills and parts of central India show goitre rates above 5 percent despite the Universal Salt Iodisation (USI) mandate.
Thyroid cancer — histology at a glance
| Cancer | Origin | Frequency | Signature |
|---|
| Papillary (PTC) | Follicular cell | 70 percent | Orphan Annie eye nuclei, psammoma bodies, nuclear grooves; lymphatic spread; BRAF V600E common; excellent prognosis |
| Follicular (FTC) | Follicular cell | 10 percent | Capsular / vascular invasion required (FNAC cannot diagnose); haematogenous — bone, lung; Hurthle cell variant oncocytic and more aggressive |
| Medullary (MTC) | Parafollicular C cell | 5 percent | Calcitonin, CEA; amyloid stroma; sporadic 75 percent vs hereditary via RET (MEN 2A, MEN 2B, familial MTC) |
| Anaplastic (ATC) | Undifferentiated follicular | 2 percent | Elderly, rapid growth, airway compromise; median survival less than 6 months |
| Thyroid lymphoma | | Rare | Background Hashimoto thyroiditis |
Papillary micro-carcinoma (PTMC)
Papillary carcinoma ≤ 10 mm without adverse features — active surveillance is now an accepted alternative to surgery for select low-risk patients (Ito protocol, Kuma Hospital), especially in the elderly.
MEN 2 (RET proto-oncogene mutations)
| Syndrome | Features |
|---|
| MEN 2A | MTC + phaeochromocytoma + primary hyperparathyroidism; RET codon 634 typical |
| MEN 2B | MTC + phaeochromocytoma + mucosal neuromas + marfanoid habitus; RET codon 918; no hyperparathyroidism |
| Familial MTC | MTC alone |
Family screening — RET testing in first-degree relatives; prophylactic total thyroidectomy at 1 year (MEN 2B) or 5 years (MEN 2A) or as directed by risk stratification.
Surgical management — choosing the operation
Hemithyroidectomy (lobectomy + isthmusectomy)
- Unilateral benign nodule with pressure symptoms.
- Indeterminate cytology (Bethesda III/IV) needing diagnosis.
- Low-risk differentiated thyroid cancer under 4 cm, no ETE, no nodal disease, no aggressive histology.
- Preserves TSH within reference range for many patients (no lifelong levothyroxine dependence).
Total thyroidectomy
- Bilateral disease.
- High-risk differentiated cancer (larger than 4 cm, extrathyroidal extension, aggressive variant, nodal disease).
- MTC — with central compartment (level VI) neck dissection; lateral neck dissection for known nodal metastases.
- Hereditary MTC in RET carriers — prophylactic total thyroidectomy at risk-directed age.
- Symptomatic multinodular goitre, retrosternal extension.
- Anaplastic cancer where surgery is feasible.
Neck dissection
- Central compartment (level VI) — routine for MTC; therapeutic for known central nodal disease in PTC.
- Lateral neck (levels II-V) — therapeutic for known lateral nodal disease.
- Prophylactic lateral neck dissection has NO survival benefit in most PTC scenarios.
Adjuvant radioactive iodine (RAI, I-131)
- After total thyroidectomy for intermediate/high-risk DTC.
- Requires TSH stimulation (thyroid hormone withdrawal or recombinant TSH) and low-iodine diet.
- Ablates thyroid remnant + treats microscopic disease; enables thyroglobulin as tumour marker.
- Doses — 30 mCi for low-risk remnant ablation, up to 150-200 mCi for known distant metastases.
- Contraindications — pregnancy, breastfeeding.
TSH suppression therapy
Levothyroxine dose is titrated to keep TSH suppressed (below 0.1 mIU/L for high-risk DTC, 0.1-0.5 for intermediate, 0.5-2 for low-risk in remission). MTC and ATC do not need TSH suppression.
Complications of thyroidectomy
| Complication | Detail |
|---|
| Recurrent laryngeal nerve (RLN) injury | 1-2 percent unilateral → hoarseness, aspiration risk; bilateral RLN injury → adductor paralysis and airway obstruction — emergency reintubation or tracheostomy |
| Superior laryngeal nerve (external branch) injury | Affects cricothyroid — loss of voice pitch, vocal fatigue (particularly noticed by singers, teachers) |
| Hypocalcaemia | Parathyroid injury or devascularisation; perioral tingling, Chvostek and Trousseau signs; check corrected calcium at 6 and 24 hours; replace with IV calcium gluconate for symptoms, oral calcium + calcitriol thereafter; permanent hypoparathyroidism in about 1-3 percent |
| Haematoma | Immediate airway emergency — open at bedside and evacuate before OR transfer |
| Hypothyroidism | Post-total thyroidectomy — lifelong levothyroxine at 1.6 μg/kg/day |
| Thyroid storm | Uncommon now with preoperative propranolol + antithyroid preparation |
| Chyle leak | After left lateral neck dissection — inferior thoracic duct injury; low-fat diet + drain; surgical repair if persistent |
| Horner syndrome | Sympathetic chain injury during lateral neck dissection |
Intraoperative nerve monitoring (IONM) — increasingly standard for the RLN and superior laryngeal nerve at high-volume centres; reduces but does not eliminate injury risk.
Advanced disease — anaplastic and metastatic MTC
- Anaplastic thyroid cancer (ATC) — targetable in a subset with BRAF V600E mutation → dabrafenib + trametinib as neoadjuvant to make previously unresectable disease resectable; airway control (tracheostomy or covered stent) is often the first priority.
- Metastatic MTC — selpercatinib, pralsetinib (selective RET inhibitors) for RET-mutant disease; vandetanib and cabozantinib for RET-agnostic salvage.
- Radioiodine-refractory DTC — lenvatinib, sorafenib (multi-TKI); trials of dabrafenib + trametinib for BRAF V600E-mutant tumours (re-differentiation).
NEET PG MCQ traps
- TSH first — low TSH → uptake scan (hot nodule usually benign); FNAC is not the first step.
- Cold nodule — needs FNAC (higher malignancy risk).
- Microcalcifications on USG — PTC (psammoma bodies).
- Orphan Annie eye nuclei + psammoma bodies + nuclear grooves — papillary carcinoma.
- BRAF V600E — most common PTC mutation; targets dabrafenib + trametinib.
- FTC diagnosis — needs capsular or vascular invasion; FNAC cannot distinguish follicular adenoma from carcinoma.
- Hurthle cell — oncocytic FTC variant, worse prognosis.
- MTC marker — calcitonin; CEA supportive; amyloid stroma on histology.
- RET codon 634 — MEN 2A; codon 918 — MEN 2B.
- MEN 2B mucosal neuromas + marfanoid habitus — pentagonal-shaped lips, tongue neuromas.
- Prophylactic total thyroidectomy — age directed by RET codon risk stratification.
- ATC — elderly, rapid growth, airway compromise; airway control first.
- Bethesda VI → total thyroidectomy (with high-risk features).
- Hemithyroidectomy — Bethesda IV nodule for diagnosis, low-risk DTC less than 4 cm.
- RAI ablation — after total thyroidectomy for intermediate/high-risk DTC.
- Bilateral RLN injury — adductor paralysis → emergency tracheostomy.
- Chvostek and Trousseau — hypocalcaemia from parathyroid injury.
- Postoperative haematoma with airway compromise — open at bedside.
- Pemberton sign — retrosternal goitre (arms up → facial plethora).
- Iodine deficiency — Sub-Himalayan India belts; USI mandate.
- PTMC — active surveillance (Ito protocol) an option in low-risk selected patients.
- Selpercatinib / pralsetinib — RET-selective TKI for metastatic MTC.
Recent updates and India context
- Bethesda 2023 refresh — refined risk-of-malignancy ranges for AUS/FLUS (10-30 percent) and follicular neoplasm (25-40 percent); explicit acknowledgement of NIFTP (Non-Invasive Follicular Thyroid Neoplasm with Papillary-like nuclei) as an indolent lesion, not cancer.
- ATA 2015 guidelines (still authoritative for most exam-relevant details) — active surveillance option for select PTMC, molecular testing for indeterminate cytology, extent of surgery based on preop risk.
- Selpercatinib (LOXO-292) — highly selective RET inhibitor; transformative in RET-mutant MTC and RET-fusion PTC. Available in India via named-patient basis.
- Dabrafenib + trametinib for BRAF V600E ATC — FDA approved; increasingly used as neoadjuvant to make anaplastic tumours resectable.
- Prophylactic thyroidectomy in MEN 2 — RET codon-directed timing; RET 918 (MEN 2B) → within first year of life; RET 634 (highest risk MEN 2A) → by 5 years.
- India tertiary practice — TMH Mumbai, AIIMS Delhi, PGIMER Chandigarh, CMC Vellore, RCC Trivandrum handle the bulk of aggressive DTC, MTC and ATC; regional cancer centres expanding RAI capacity.
- Iodine deficiency status — India remains iodine sufficient at the national level (median urinary iodine over 100 μg/L) but pockets in Sub-Himalayan states, Chhattisgarh, Odisha, and parts of Northeast persist below WHO targets, feeding endemic goitre.
- Rising incidental PTMC in young Indian women — driven partly by increased neck ultrasonography during infertility, thyroid function and general health check-ups; drives the active surveillance debate.
Frequently asked questions
How do TSH, USG and FNAC combine to work up a thyroid nodule?
Start with serum TSH. A low TSH suggests a functioning (hot) nodule — pursue a Tc-99m or I-123 uptake scan first; a truly hyperfunctioning nodule is almost never malignant and FNAC is deferred. A normal or high TSH triggers ultrasound stratification using ACR TI-RADS or ATA sonographic categories — features like hypoechogenicity, taller-than-wide shape, microcalcifications, irregular margins and extrathyroidal extension raise malignancy risk. FNAC is then guided by TI-RADS category plus nodule size, with cytology reported using the Bethesda 2023 system (categories I to VI, each with an implied risk of malignancy and management pathway).
What is the Bethesda 2023 system and how does each category guide management?
Bethesda 2023 stratifies thyroid FNAC into six categories with implied malignancy risk: I nondiagnostic (5-10 percent risk — repeat FNAC), II benign (0-3 percent — clinical follow-up), III AUS/FLUS (10-30 percent — repeat FNAC or molecular testing), IV follicular neoplasm or suspicious for follicular neoplasm (25-40 percent — hemithyroidectomy or molecular testing), V suspicious for malignancy (60-75 percent — hemithyroidectomy at minimum), VI malignant (97-99 percent — total thyroidectomy for high-risk features). Molecular assays (Afirma GSC, ThyroSeq v3) refine the indeterminate categories III and IV.
How do papillary, follicular, medullary and anaplastic thyroid cancers differ?
Papillary thyroid carcinoma (PTC, about 70 percent) has Orphan Annie-eye nuclei, psammoma bodies and nuclear grooves; spreads via cervical lymphatics; excellent prognosis. Follicular thyroid carcinoma (FTC, about 10 percent) needs capsular or vascular invasion for the diagnosis of malignancy — FNAC cannot distinguish adenoma from carcinoma; spreads haematogenously to bone and lung; Hurthle cell (oncocytic) variant is more aggressive. Medullary thyroid carcinoma (MTC, about 5 percent) arises from parafollicular C cells, secretes calcitonin and CEA, and is sporadic or hereditary via RET oncogene (MEN 2A, MEN 2B). Anaplastic thyroid carcinoma (ATC, about 2 percent) is undifferentiated, presents in the elderly with rapid airway compromise, and has median survival under 6 months.
When do you choose hemithyroidectomy vs total thyroidectomy?
Hemithyroidectomy (lobectomy plus isthmusectomy) suits unilateral benign nodules with pressure symptoms, indeterminate cytology needing diagnosis, and low-risk differentiated thyroid cancers under 4 cm without extrathyroidal extension, nodal metastases or aggressive histology. Total thyroidectomy is indicated for bilateral disease, larger or high-risk differentiated cancers, medullary thyroid carcinoma (with prophylactic central compartment neck dissection), hereditary MTC in RET carriers, symptomatic multinodular goitre, retrosternal extension, and any anaplastic cancer where surgery is feasible. Total thyroidectomy also enables adjuvant radioactive iodine ablation and simplifies thyroglobulin surveillance in differentiated cancer.
What are the key thyroidectomy complications and how do you manage them?
Recurrent laryngeal nerve injury (1-2 percent unilateral) causes hoarseness; bilateral RLN injury causes bilateral vocal cord adductor paralysis and can be an airway emergency needing immediate reintubation or tracheostomy. External branch of superior laryngeal nerve injury changes voice pitch and vocal fatigue. Hypocalcaemia from parathyroid injury or devascularisation presents with perioral tingling, Chvostek and Trousseau signs — check corrected calcium at 6 and 24 hours, replace with IV calcium gluconate for symptomatic patients, then oral calcium plus calcitriol. Postoperative haematoma with expanding neck swelling and airway compromise mandates immediate bedside wound reopening. Long-term — hypothyroidism after total thyroidectomy requires lifelong levothyroxine with TSH-driven titration.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: July 2026
